from recombinantly produced polypeptides and/or as synthetic peptides. [0135] IMP/MC complex formulations may be prepared with other immunotherapeutic agents including, but not limited to, cytokine, adjuvants and antibodies, such as anti-tumor antibodies and derivatives thereof.